/
Metabolic & Endocrine
Familial Hypercholesterolemia
13
Pipeline Programs↗
25
Active Trials↗
24
Companies Involved↗
Familial Hypercholesterolemia is an emerging landscape with 13 programs across 24 companies. The most active players are CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Qilu Pharmaceutical Co., Ltd., Verve Therapeutics, Inc.. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 37
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
10 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 92% of 13 pipeline programs.
Analysis
Trial Status
96
clinical trials
Completed58 · 60%
Recruiting13 · 14%
Not yet recruiting8 · 8%
Unknown status5 · 5%
Terminated5 · 5%
Active, not recruiting3 · 3%
Other4 · 4%
Clinical Trials
Trial Activity
96 trials
Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH): A Real World, Prospective and Retrospective, Observational Study
Recruiting·FFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)·N/A·NCT07447648·52 enrolled
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 1·NCT06461702·13 enrolled
Screening for Familial Hypercholesterolemia in Children
Recruiting·—·N/A·NCT06555120·300 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)